Press coverage about Lannett (NYSE:LCI) has trended somewhat positive on Saturday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lannett earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.1030137662478 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of Lannett (LCI) opened at $24.05 on Friday. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.52 and a quick ratio of 1.90. Lannett has a 12-month low of $14.90 and a 12-month high of $30.35. The stock has a market cap of $906.68, a P/E ratio of 21.47, a P/E/G ratio of 1.74 and a beta of 2.84.

Lannett (NYSE:LCI) last released its earnings results on Monday, November 6th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.08. Lannett had a net margin of 6.67% and a return on equity of 18.23%. The business had revenue of $155.00 million for the quarter, compared to analysts’ expectations of $153.62 million. During the same period last year, the company earned $0.77 earnings per share. The company’s quarterly revenue was down 4.1% on a year-over-year basis. analysts anticipate that Lannett will post 3.04 EPS for the current fiscal year.

Several research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Lannett from a “buy” rating to a “hold” rating in a report on Wednesday, December 13th. Oppenheimer reiterated a “hold” rating on shares of Lannett in a research note on Monday, December 11th. ValuEngine upgraded shares of Lannett from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Finally, BMO Capital Markets increased their price target on shares of Lannett from $20.00 to $22.00 and gave the stock a “market perform” rating in a research note on Monday, November 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $23.60.

In other Lannett news, major shareholder David Farber sold 9,816 shares of Lannett stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $30.05, for a total transaction of $294,970.80. Following the transaction, the insider now directly owns 4,190,169 shares of the company’s stock, valued at $125,914,578.45. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Arthur P. Bedrosian sold 42,000 shares of Lannett stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $25.50, for a total transaction of $1,071,000.00. Following the transaction, the chief executive officer now directly owns 636,616 shares in the company, valued at $16,233,708. The disclosure for this sale can be found here. Insiders sold 130,000 shares of company stock worth $3,430,991 over the last three months. Corporate insiders own 14.72% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Lannett (LCI) Stock Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at

Lannett Company Profile

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Insider Buying and Selling by Quarter for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with's FREE daily email newsletter.